Navigation Links
Biodel Obtains Exclusive License to Aegis Therapeutics' Technologies for Development and Commercialization of Glucagon Pharmaceutical Formulations
Date:6/8/2012

ase contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Such forward-looking statements include statements about future activities related to the clinical development plans for the company's drug candidates, including the potential timing, design and outcomes of clinical trials; and the company's ability to develop and commercialize product candidates.  Forward-looking statements represent our management's judgment regarding future events.  All statements, other than statements of historical facts, including statements regarding our strategy, future operations, future clinical trial results, future financial position, future revenues, projected costs, prospects, plans and objectives of management are forward-looking statements.  The words "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "projects," "should," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.  The company's forward-looking statements are subject to a number of known and unknown risks and uncertainties that could cause actual results, performance or achievements to differ materially from those described or implied in the forward-looking statements, including, but not limited to, the success of our product candidates, particularly our proprietary formulations of injectable insulin that are designed to be absorbed more rapidly than the "rapid-acting" mealtime insulin analogs presently used to treat patients with Type 1 and Type 2 diabetes; our ability advance a proprietary insulin formulation into a Phase 2 clinical trial in a timely manner; our ability to conduct pivotal clinical trials, other tests or analyses required by the U.S. Food and Drug Administration, or FDA, to secure approval to commercialize a proprietary formulation
'/>"/>
SOURCE Biodel Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Biodels Intellectual Property Position Strengthened for Ultra-Rapid-Acting Insulin Programs by Notice of Intent to Grant from European Patent Office
2. Biodel to Report Second Quarter Fiscal Year 2012 Financial Results on May 10, 2012
3. Islet Sciences Announces Exclusive License Agreement with Yale University to Commercialize an Early Beta Cell Destruction and Diabetes Diagnostic
4. Exclusive Industry Panel for Medical Device Developers - "The Great Innovators: A Sit-Down Chat with Dr. Thomas Fogarty & Dean Kamen"
5. SurgLine International, Inc. Chief Executive Officer, Thomas Toland, Exclusive Interview on Stock Traders Talk Radio
6. Debiopharm and Vifor Pharma Sign an Exclusive Agreement for the Distribution and Commercialization of Pamorelin®LA in Switzerland - A Drug Treatment for Prostate Cancer and Endometriosis
7. CASiGEN Pharma Receives A World-wide Exclusive License From GIBH To Bring New Potential Diabetes Treatments To The Global Market
8. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
9. MetaStat, Inc. Executes Two New Licenses
10. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
11. Ventana licenses Gen-Probe IP for measuring ERG protein in prostate cancer patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), ... that its CGuard TM Embolic Prevention System reported positive ... Musialek , at the EuroPCR conference on May ... PARADIGM, an investigator-initiated P rospective evaluation of ... revascularization I n symptomatic and increased-risk asymptomatic carotid artery ...
(Date:5/22/2015)... 2015 AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX ... and commercialization of innovative therapies for the treatment of ... executive officer Howie Rosen will be presenting ... Tim Morris will be presenting at JMP ... are as follows: Jefferies 2015 Healthcare Conference ...
(Date:5/21/2015)... , May 21, 2015 ... announced the addition of the "Market Assessment ... Europe" report to their offering. ,     (Logo: ... of the respiratory imaging diagnostics market in ... Europe . The service provides detailed ...
Breaking Medicine Technology:InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 2InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 3InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 4AcelRx Pharmaceuticals to Present at Two Upcoming Investor Conferences In June 2United States and Europe Respiratory Diagnostics Market Assessment 2015 2
(Date:5/22/2015)... Omar Ahmad Barrada, a junior at ... the 2015 Congress of Future Medical Leaders in Boston, ... of “America’s highest achieving high school students.” , “I’m ... new goals and learn better study habits,” said Omar. ... which we can ask the surgeons questions.” , The ...
(Date:5/22/2015)... NY (PRWEB) May 22, 2015 Hands ... that June 17, 2015, the Annual One Day Sale ... Since 2007, Hands On HCMT offers drastically reduced certificates one ... and estheticians have enough sessions, through what used to be ... is wonderful for the community as well. This once a ...
(Date:5/22/2015)... 22, 2015 Family, friends, students, colleagues, ... surgical oncologist, Dr. LaSalle D. Leffall, on Monday, May ... began after Grand Rounds in the hospital’s Tower Auditorium. ... outside the auditorium, trying to keep the secret. “I’d ... he sees me, he’ll know something is up,” she ...
(Date:5/22/2015)... May 22, 2015 Coordinating care ... difficult process. Historically providers have not been reimbursed ... Starting in 2015, Medicare has paved the way ... Thanks to the launch of Oculus Health ... health systems using the platform will now be ...
(Date:5/22/2015)... According to a new Aegis Living Study on ... likely to worry about what will happen to their memory ... 69% Silent Generation), which may help explain why nearly half ... particularly Millennials (47%), Gen X’ers (51%), and Boomers (43%). The ... among more than 2,000 U.S. adults ages 18+. , ...
Breaking Medicine News(10 mins):Health News:Milton Hershey School Student Chosen for Congress of Future Medical Leaders 2Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Announces Their Eighth Annual One Day Sale on Gift Certificates Will Take Place on June 17, 2015 2Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Announces Their Eighth Annual One Day Sale on Gift Certificates Will Take Place on June 17, 2015 3Health News:Colleagues Surprise Dr. LaSalle Leffall with 85th Birthday Celebration 2Health News:Oculus Health Care Coordination Platform Officially Launched 2Health News:Oculus Health Care Coordination Platform Officially Launched 3Health News:Oculus Health Care Coordination Platform Officially Launched 4Health News:New Study Reveals America’s Fear of Aging 2Health News:New Study Reveals America’s Fear of Aging 3
... for heart disease, 56% risk of ischemic stroke, study finds ... secondhand smoke at home or in the workplace had a ... to women who weren,t exposed, a new study says. , ... of secondhand smoke on peripheral artery disease in women," lead ...
... are uncovering more evidence that a virus they recently discovered ... deadly form of skin cancer. , The findings, published in ... the National Academy of Sciences, put to rest the ... that were the case, the virus would be a passenger ...
... help women to,take control of their health and improve ... Women today placed the first,bilingual, touch-activated Women,s Wellness Guide ... This is the first of 13 kiosks to ... tendency to care for everyone else but themselves and,their ...
... Sept. 22 Biomoda, Inc.,(OTC Bulletin Board: BMOD) ... expanded its intellectual property portfolio,with approval from the ... and CyPath(R)., "We are pleased to receive ... portfolio," said John Cousins, Biomoda president. "It is ...
... Ill. September 22, 2008 A study appearing ... Journal of Medicine shows that among individuals with no ... risk of colorectal cancer is extremely low. The data provides ... longer after a normal colonoscopic examination. , "This research is ...
... patients who receive stereotactic radiosurgery (SRS) and whole brain ... tumors have more than twice the risk of developing ... alone, according to new research from The University of ... of the phase III randomized trial were presented at ...
Cached Medicine News:Health News:Women's Peripheral Artery Disease Tied to Secondhand Smoke 2Health News:Pitt research indicates new virus is culprit, not bystander, in deadly skin cancer 2Health News:Pennsylvania Commission for Women Delivers First Women's Wellness Guide Kiosk to Allegheny County Jail 2Health News:U.S. Patent Office Grants Biomoda Registration for Trademarks 2Health News:Risk of colorectal cancer extremely low 5 years after a normal colonoscopy screening 2Health News:Whole brain radiation increases risk of learning and memory problems in cancer patients 2Health News:Whole brain radiation increases risk of learning and memory problems in cancer patients 3
Greenberg micro instrument holder is a flexbar arm used to hold micro instruments used repeatedly within retracted fields. Holds instruments with shafts up to 1/8 in diameter....
Greenberg universal retractor case, with four compartments to hold various components....
Length-9 (229 mm) Tapered retractor blades....
Kit is supplied with four secondary bars. Secondary bars attach to primary bar. Length 12 (305 mm)....
Medicine Products: